Compare Adecoagro SA (AGRO) vs Biogen Inc (BIIB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adecoagro SA vs Biogen Inc — how do they compare? Adecoagro SA trades at $10.23 (market cap $1.39B), while Biogen Inc trades at $201.76 (market cap $30.37B). The key difference: Biogen Inc is far larger — about 21.8× Adecoagro SA's market cap, and Adecoagro SA pays a 3.08% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| AGRO | BIIB | |
|---|---|---|
Market Cap | $1.39B | $30.37B |
Sector | Technology | Health |
52-Week High | $15.25 | $216.63 |
52-Week Low | $7.13 | $122.68 |
Enterprise Value | $3.42B | $32.65B |
Dividend Yield | 3.08% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AGRO trades at $9.48, down 1.66% today, with a bearish technical signal despite neutral oscillators. The company reported mixed quarterly results, missing Q1 2026 EPS estimates but showing strong adjusted EBITDA growth. Valuation metrics appear attractive with P/S of 0.71 and P/B of 0.78, though profitability remains weak with a 0.91% net margin. Recent news highlights innovation in agriculture operations and a declared $0.12 dividend for H1 2026.
The stock offers value appeal with below-market multiples and analyst consensus target of $12.75 implying 34% upside. However, inconsistent earnings performance and negative net income in 2025 pose execution risks. The bearish technical trend and competitive pressures in sustainable agriculture require careful monitoring for potential investors.
Biogen (BIIB) trades at $205.70, down 4.82% today, with a bullish technical signal and strong earnings beat history. The stock shows solid fundamentals with a P/E of 22.42, net income margin of 13.81%, and positive cash flow trends. Recent acquisitions like RayThera for up to $1 billion aim to expand its immunology pipeline, while Alzheimer's portfolio updates at AAIC 2026 provide near-term catalysts. Analyst consensus is bullish with a $224.82 price target, though legal investigations and legacy drug sales declines pose headwinds.
The outlook remains positive given earnings momentum and strategic pipeline investments, but investors face risks from ongoing legal probes and competitive pressures. The stock offers upside to consensus targets if new drug launches offset revenue declines, but volatility may persist amid sector rotation and regulatory scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adecoagro SA
Adecoagro is a South American agricultural company. It operates a diversified business including farming crops, rice, and dairy, as well as producing sugar, ethanol, and renewable energy from its industrial facilities.
Read more on AGRO →About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →
